Skip to main content

You are using an old and unsupported browser. Most core functionality will not work. Please upgrade to a supported browser - Google Chrome

Parkinson's Australia National Symposium - Prosper 2020
Parkinson's Australia National Symposium 'Prosper' 2020

    Emerging Concepts for Precision Medicine in Parkinson's

    Presentation Description

    To date, no causative treatments are available for common neurodegenerative diseases like Parkinson’s disease (PD). Previously failed trials did not account for the clinical and pathophysiological heterogeneity of PD. Genetics of PD provided first insight into the complexity of this most common neurodegenerative movement disorder and delineated relevant subgroups of patients, who share an underlying molecular pathology. Novel patient-based models from monogenic forms of PD allowed to dissect mechanisms of neurodegeneration and define a first entry point to screen for disease-modifying compounds for more targeted therapies. Using neurons derived from induced pluripotent stem cells we implemented a comprehensive high-troughput/high-content screening (HTS/HCS) platform for discovering neuroprotective compounds in monogenic forms of PD. Here we provide first promising results to identify mechanism-based interventions in subgroups of PD patients using advanced cellular models.

    During the last years, there has been a rapid evolution in novel technologies, e.g. next generation sequencing technologies or device-assisted registrations of PD symptoms. This is linked with a dramatic increase in high quality data characterizing PD at different levels and enables novel strategies for patient stratification and identification of markers for therapeutic outcome, that can be translated into precision medicine approaches and clinical decision support. Here we provide evidence for genetic predictors of therapeutic outcome in PD. These implementation of novel technologies allow for a more direct participation of patients in ongoing research and strengthen patient’s autonomy and responsibility for future research.
    genetic stratification, induced pluripotent stem cells, deep phenotyping, device-based assessments, stratified treatment, clinical decision support


    Other Suggested Presentations

    20 November 2020 2:20 pm
    Room 2
    Legal Insights: At work, ending employment and estate planning
    Laura Evans-McKendry, Nick Scott

    20 November 2020 3:00 pm
    Room 3
    Break (20 mins)

    21 November 2020 2:20 pm
    Room 3
    Exercise program preferences of people with Parkinson’s disease
    Serene Paul